The Subject Expert Committee (SEC) is slated to hold a meeting to provide emergency use authorisation (EUA) to Russia’s Sputnik Light, the one-shot Covid vaccine, on Tuesday, sources said.
The vaccine maker has submitted data on the efficacy of Sputnik Light. The Russian Direct Investment Fund (RDIF) earlier said that it submitted data from additional clinical trials to India’s regulator. The company expects the vaccine to be authorised in India soon.
Sputnik Light (the one-shot vaccine based on human adenovirus serotype 26, the first component of the Sputnik V) is a standalone vaccine and a universal booster. Unlike the earlier vaccine which has two different vaccine components, Ad 26 and Ad 5, this will just be one shot.
The Gamelaya Institute in Moscow, which made the Russian vaccine, said all individuals who had received a single shot of Sputnik Light booster dose developed neutralising antibodies against the Omicron Covid-19 variant, even after two-three months of being injected with the vaccine.
“Based on these data, the expected efficacy of Sputnik V vaccine with Sputnik Light booster against Omicron could be more than 80%,” the premier research centre said in a statement.
In a study published in Medxiv, a team of Harvard researchers demonstrated that boosting Pfizer vaccine with Ad26 vector produces optimal durable protection against Omicron.
“Sputnik Light is based on Ad26 vector and is the universal booster for other vaccines against all mutations. Ad26 boosting produces growing antibodies & high T-cells against Omicron, while control Pfizer boost produces fading antibodies & lower T-Cells,” said Sputnik V’s official Twitter handles.
The RDIF, Russia’s sovereign wealth fund, said it has also provided India’s regulator with documents for registering Sputnik M, a variant of the vaccine for adolescents aged 12-17.
BHARAT BIOTECH NASAL VAX
The SEC is also set to discuss Bharat Biotech’s intranasal vax for trials as a booster dose for both Covaxin and Covishied.
Bharat Biotech aims to conduct clinical trials on 5,000 subjects (50% vaccinated with Covishield & 50% with Covaxin). Sources say that a nasal dose can be administered after 6 months of the second dose.
This is a separate study from the on-going nasal vaccine trials being conducted which are in the phase 3 stages.